Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25236481 | 0.90 | — | — | |
| SCHEMBL25281090 | 0.79 | IRAK4 (0.39) | IRAK4TGFBR1CNR2 | |
| SCHEMBL25280957 | 0.77 | SYK (0.35) | IRAK4TGFBR1 | |
| SCHEMBL25229815 | 0.77 | IRAK4 (0.41) | IRAK4TGFBR1CNR2 | |
| SCHEMBL25281063 | 0.77 | IRAK4 (0.41) | IRAK4TGFBR1CNR2 | |
| SCHEMBL25229559 | 0.76 | IRAK4 (0.33) | IRAK4CSNK2A2CSNK2A1 | |
| SCHEMBL25231457 | 0.76 | SYK (0.35) | IRAK4CSNK2A2CSNK2A1 | |
| SCHEMBL25274729 | 0.76 | IRAK4 (0.38) | IRAK4TGFBR1CNR2 | |
| SCHEMBL25274730 | 0.75 | IRAK4 (0.37) | IRAK4 | |
| SCHEMBL31178099 | 0.71 | TGFBR1 (0.51) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473290-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL MYERS-SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | claimed |
| EP-3935058-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2024-08-21 | — | — | EP | claimed |
| CN-114222744-B | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFNα response | 百时美施贵宝公司 | 2024-06-25 | — | — | CN | claimed |
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-15 | — | — | US | claimed |
| CN-114222744-A | Imidazopyridazine compounds useful as IL-12, IL-23 and/or IFN alpha response modulators | 百时美施贵宝公司 | 2022-03-22 | — | — | CN | claimed |
| US-12473290-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL MYERS-SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| EP-3935058-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-114222744-B | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFNα response | 百时美施贵宝公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-15 | — | — | US | disclosed |
| CN-114222744-A | Imidazopyridazine compounds useful as IL-12, IL-23 and/or IFN alpha response modulators | 百时美施贵宝公司 | 2022-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, JAK3, IFNAR1 | IRAK4 22/4885TGFBR1 393/4885HPGDS 1640/4885 |
| US-12473290-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | TYK2, JAK3, IFNAR1 | IRAK4 22/4885TGFBR1 393/4885HPGDS 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.